{"id":53614,"date":"2023-09-20T09:48:35","date_gmt":"2023-09-20T09:48:35","guid":{"rendered":"https:\/\/medsname.com\/febutaz\/"},"modified":"2026-04-30T10:25:11","modified_gmt":"2026-04-30T10:25:11","slug":"febutaz","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/febutaz\/","title":{"rendered":"Febutaz"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Febutaz<\/strong> obsahuje febuxostat 40 mg \/ 80 mg<\/strong> v\u00fdrobce Sun Pharma. Pou\u017e\u00edv\u00e1 se k dlouhodob\u00e9mu sni\u017eov\u00e1n\u00ed hladiny kyseliny mo\u010dov\u00e9 v s\u00e9ru u dosp\u011bl\u00fdch s chronickou dnou (l\u00e9\u010dba sni\u017euj\u00edc\u00ed hladinu ur\u00e1t\u016f) \u2014 v\u010detn\u011b pacient\u016f s ur\u00e1tov\u00fdmi ledvinov\u00fdmi kameny. U\u017e\u00edvejte p\u0159esn\u011b podle pokyn\u016f l\u00e9ka\u0159e \u2014 sami si d\u00e1vku neupravujte.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

\ud83d\udd12 \u0160ifrovan\u00e9 platby<\/strong> \u00b7 \ud83d\udcb3 Ov\u011b\u0159en\u00fd platebn\u00ed procesor<\/strong> \u00b7 \ud83d\ude9a Doprava do cel\u00e9ho sv\u011bta<\/strong> \u00b7 \u2b50 4,9\/5 od 1 400+ z\u00e1kazn\u00edk\u016f<\/strong><\/div>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou odes\u00edl\u00e1ny v neutr\u00e1ln\u00edch obalech od na\u0161ich partnersk\u00fdch distribu\u010dn\u00edch center a jsou chr\u00e1n\u011bny na\u0161\u00edm Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>. Slou\u017eili jsme ji\u017e 1 400+ ov\u011b\u0159en\u00fdm z\u00e1kazn\u00edk\u016fm<\/strong> s pr\u016fm\u011brn\u00fdm hodnocen\u00edm 4,9\/5<\/strong> nap\u0159\u00ed\u010d v\u00edce ne\u017e 600 l\u00e9ky.<\/p>\n

\n

\u26a0 Kardiovaskul\u00e1rn\u00ed opatrnost \u2014 alopurinol je preferovan\u00e1 l\u00e9\u010dba prvn\u00ed volby pro sn\u00ed\u017een\u00ed hladiny ur\u00e1t\u016f<\/strong><\/p>\n

Studie CARES z roku 2018 CARES trial<\/strong> prok\u00e1zala vy\u0161\u0161\u00ed kardiovaskul\u00e1rn\u00ed mortalitu a celkovou \u00famrtnost u febuxostatu ve srovn\u00e1n\u00ed s alopurinolem u pacient\u016f s dnou A zaveden\u00fdm kardiovaskul\u00e1rn\u00edm onemocn\u011bn\u00edm. Studie z roku 2020 FAST trial<\/strong> nezjistil nadm\u011brn\u00e9 riziko v evropsk\u00e9 populaci. Hlavn\u00ed sm\u011brnice (ACR 2020, EULAR 2016) doporu\u010duj\u00ed alopurinol jako l\u00e9k prvn\u00ed volby<\/strong>; febuxostat je vyhrazen pro pacienty, kte\u0159\u00ed nesn\u00e1\u0161ej\u00ed nebo nedosahuj\u00ed c\u00edlov\u00fdch hodnot na alopurinolu, nebo kte\u0159\u00ed maj\u00ed kontraindikace HLA-B*5801. P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby proberte kardiovaskul\u00e1rn\u00ed anamn\u00e9zu s p\u0159edepisuj\u00edc\u00edm l\u00e9ka\u0159em.<\/p>\n<\/div>\n

Co je Febutaz a jak p\u016fsob\u00ed<\/h2>\n

Febutaz obsahuje febuxostat<\/strong>, , nepurinov\u00fd selektivn\u00ed inhibitor xanthinoxid\u00e1zy<\/strong>. Blokov\u00e1n\u00edm xanthinoxid\u00e1zy zastavuje p\u0159em\u011bnu hypoxantinu a xantinu na kyselinu mo\u010dovou, \u010d\u00edm\u017e sni\u017euje s\u00e9rovou hladinu ur\u00e1t\u016f. Na rozd\u00edl od alopurinolu (purinov\u00e9ho analogu) je febuxostat metabolizov\u00e1n p\u0159ev\u00e1\u017en\u011b v j\u00e1trech, tak\u017ee jej lze pou\u017e\u00edt u m\u00edrn\u00fdch a\u017e st\u0159edn\u00edch ren\u00e1ln\u00edch poruch bez \u00fapravy d\u00e1vkov\u00e1n\u00ed.<\/p>\n

Febutaz je schv\u00e1len pro dlouhodobou l\u00e9\u010dbu hyperurik\u00e9mie u pacient\u016f s dnou<\/strong>, v\u010detn\u011b tof\u00f3zn\u00ed dny. Nen\u00ed ur\u010den k l\u00e9\u010db\u011b akutn\u00edho z\u00e1chvatu dny; z\u00e1chvaty se l\u00e9\u010d\u00ed NSAID, kolchicinem nebo kortikosteroidy.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a zp\u016fsob u\u017e\u00edv\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n
Skupina pacient\u016f<\/th>\nDoporu\u010den\u00e1 d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Dosp\u011bl\u00ed s chronickou dnou \u2014 po\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/td>\n40 mg jednou denn\u011b<\/strong><\/td>\n<\/tr>\n
Po 2\u20134 t\u00fddnech zv\u00fd\u0161it d\u00e1vku, pokud s\u00e9rov\u00fd ur\u00e1t > 0,36 mmol\/L (6 mg\/dL)<\/td>\nZv\u00fd\u0161it na 80 mg jednou denn\u011b<\/strong><\/td>\n<\/tr>\n
T\u011b\u017ek\u00e9 ren\u00e1ln\u00ed posti\u017een\u00ed (eGFR <30)<\/td>\nPou\u017e\u00edvejte opatrn\u011b; \u00fadaje jsou omezen\u00e9; zva\u017ete alternativu<\/td>\n<\/tr>\n
T\u011b\u017ek\u00e9 jatern\u00ed po\u0161kozen\u00ed (Child-Pugh C)<\/td>\nVyhn\u011bte se \u2014 nebylo studov\u00e1no<\/td>\n<\/tr>\n
Tof\u00f3zn\u00ed dna \/ velmi vysok\u00e1 v\u00fdchoz\u00ed hladina ur\u00e1t\u016f<\/td>\nM\u016f\u017ee b\u00fdt nutn\u00e9 za\u010d\u00edt s 80 mg pod odborn\u00fdm dohledem<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

U\u017e\u00edvejte ka\u017ed\u00fd den ve stejnou dobu, s j\u00eddlem nebo bez j\u00eddla.<\/strong> Pokra\u010dujte neomezen\u011b dlouho \u2014 dna je chronick\u00e9 onemocn\u011bn\u00ed. C\u00edlov\u00e1 hladina s\u00e9rov\u00fdch ur\u00e1t\u016f je obvykle < 0,36 mmol\/L (< 6 mg\/dL)<\/strong>; u tof\u00f3zn\u00ed dny < 0,30 mmol\/L (< 5 mg\/dL) pro rozpou\u0161t\u011bn\u00ed tof\u016f.<\/p>\n

\n

\u2705 P\u0159edepisujte sou\u010dasn\u011b profylaxi akutn\u00edch z\u00e1chvat\u016f po dobu prvn\u00edch 6 m\u011bs\u00edc\u016f<\/strong><\/p>\n

Zah\u00e1jen\u00ed jak\u00e9koli terapie sni\u017euj\u00edc\u00ed hladinu ur\u00e1t\u016f m\u016f\u017ee vyvolat dnav\u00e9 z\u00e1chvaty<\/strong> p\u0159i uvol\u0148ov\u00e1n\u00ed krystal\u016f z kloub\u016f. Pokyny ACR a EULAR doporu\u010duj\u00ed profylaktick\u00e9 pod\u00e1v\u00e1n\u00ed kolchicinu 0,5\u20131 mg\/den<\/strong> nebo nesteroidn\u00ed protiz\u00e1n\u011btliv\u00e9 l\u00e9ky (NSAID)<\/strong> po dobu nejm\u00e9n\u011b 3\u20136 m\u011bs\u00edc\u016f p\u0159i zah\u00e1jen\u00ed febuxostatu \u2014 pokud dojde k z\u00e1chvatu, nep\u0159est\u00e1vejte s febuxostatem.<\/p>\n<\/div>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Vedlej\u0161\u00ed \u00fa\u010dinek<\/th>\nFrekvence<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
Dnav\u00fd z\u00e1chvat (\u010dasn\u00e1 terapie)<\/td>\nVelmi \u010dast\u00e9 v prvn\u00edch 6 m\u011bs\u00edc\u00edch<\/td>\nPou\u017e\u00edvejte profylaxi; nep\u0159eru\u0161ujte febuxostat<\/td>\n<\/tr>\n
Zv\u00fd\u0161en\u00ed jatern\u00edch enzym\u016f<\/td>\nB\u011b\u017en\u00e9<\/td>\nKontrolujte jatern\u00ed testy na za\u010d\u00e1tku, po 2 m\u011bs\u00edc\u00edch a pot\u00e9 pravideln\u011b<\/td>\n<\/tr>\n
Bolest hlavy<\/td>\nB\u011b\u017en\u00e9<\/td>\nObvykle m\u00edrn\u00e9<\/td>\n<\/tr>\n
Pr\u016fjem, nevolnost<\/td>\nB\u011b\u017en\u00e9<\/td>\nU\u017e\u00edvejte s j\u00eddlem<\/td>\n<\/tr>\n
Vyr\u00e1\u017eka<\/td>\nM\u00e9n\u011b \u010dast\u00e9<\/td>\nP\u0159eru\u0161te p\u0159i rozs\u00e1hl\u00fdch projevech; vz\u00e1cn\u00e9 p\u0159\u00edpady z\u00e1va\u017en\u00fdch ko\u017en\u00edch reakc\u00ed<\/td>\n<\/tr>\n
Kardiovaskul\u00e1rn\u00ed p\u0159\u00edhody (u stanoven\u00e9ho KVO)<\/td>\nSign\u00e1l studie CARES<\/td>\nProkonzultujte s kardiologem; zva\u017ete alopurinol<\/td>\n<\/tr>\n
Hepatotoxicita (z\u00e1va\u017en\u00e1)<\/td>\nVz\u00e1cn\u00e9<\/td>\nP\u0159eru\u0161it a vyhledat odborn\u00e9 posouzen\u00ed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Interakce l\u00e9k\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n
Kombinace<\/th>\n\u00da\u010dinek<\/th>\n\u00da\u010dinek<\/th>\n<\/tr>\n<\/thead>\n
Azathioprin, merkaptopurin<\/td>\nV\u00fdrazn\u00e9 zv\u00fd\u0161en\u00ed hladin 6-merkaptopurinu \u2014 toxicita kostn\u00ed d\u0159en\u011b<\/td>\nVyvarujte se kombinace<\/strong><\/td>\n<\/tr>\n
Theofylin<\/td>\nHladiny theofylinu mohou stoupat<\/td>\nSledujte<\/td>\n<\/tr>\n
NSAID, kolchicin, n\u00edzk\u00e9 d\u00e1vky aspirinu<\/td>\nPou\u017e\u00edv\u00e1no spole\u010dn\u011b k profylaxi vzplanut\u00ed \u2014 standardn\u00ed sch\u00e9ma<\/td>\nNejedn\u00e1 se o skute\u010dnou interakci; lze p\u0159edepisovat sou\u010dasn\u011b<\/td>\n<\/tr>\n
Diuretika (thiazidov\u00e1, kli\u010dkov\u00e1)<\/td>\nZvy\u0161uj\u00ed s\u00e9rovou hladinu ur\u00e1t\u016f \u2014 m\u016f\u017ee b\u00fdt nutn\u00e1 vy\u0161\u0161\u00ed d\u00e1vka febuxostatu<\/td>\nMonitorovat c\u00edlovou hladinu ur\u00e1t\u016f<\/td>\n<\/tr>\n
Warfarin<\/td>\n\u017d\u00e1dn\u00e1 klinicky v\u00fdznamn\u00e1 interakce<\/td>\nStandardn\u00ed monitorov\u00e1n\u00ed INR<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Kdo by nem\u011bl u\u017e\u00edvat Febutaz<\/h2>\n